Luc Le Fournier1, Matthieu Delion1, Maxime Esvan2, Emilie De Carli3, Céline Chappé4, Philippe Mercier1, Philippe Menei1, Laurent Riffaud5,6. 1. Department of Pediatric Neurosurgery, Angers University Hospital, Angers, France. 2. Department of Biostatistics, Rennes University Hospital, Rennes, France. 3. Department of Pediatric Oncology, Angers University Hospital, Angers, France. 4. Department of Pediatric Oncology, Rennes University Hospital, Rennes, France. 5. Department of Pediatric Neurosurgery, Rennes University Hospital, Rennes, France. laurent.riffaud@chu-rennes.fr. 6. INSERM, UMR 1099 LTSI, University of Rennes 1, Rennes, France. laurent.riffaud@chu-rennes.fr.
Abstract
PURPOSE: Presence of metastases in newly diagnosed pediatric posterior fossa tumors (PFT) is not a rare situation, but optimal treatment of associated hydrocephalus in these children has remained undetermined. METHODS: Twenty-nine children treated between January 2005 and December 2015 for a metastatic PFT associated with hydrocephalus constituted the study cohort. Patients were divided into three groups: ventriculoperitoneal shunt (VPS), endoscopic third ventriculostomy (ETV), and temporary ventricular drainage before or during tumor resection (PVD). RESULTS: There were 4 VPS, 18 ETV, and 7 PVD. The global incidence of CSF diversion failure was 52%. No case of dysfunction or dissemination of metastatic cells occurred in the VPS group. Recurrence of hydrocephalus occurred in 55% of the ETV group. Presence of multiple macroscopic metastases and CSF metastatic cells after tumor surgery was associated with ETV failure. Fifty-seven percent of the children in the PVD group were reoperated after an average time of 53 days. Specific oncologic treatment was initiated earlier in the VPS group (11 days) compared to ETV (27 days) and PVD (23 days) groups. CONCLUSIONS: ETV should be avoided in cases of multiple macroscopic metastases, and children who underwent ETV must be followed carefully when metastatic cells are present in CSF after tumor surgery. External ventricular drainage before or during surgical removal should not be considered as a final option to treat hydrocephalus. VPS remains a safe alternative in this situation and allows an early specific oncologic treatment.
PURPOSE: Presence of metastases in newly diagnosed pediatric posterior fossa tumors (PFT) is not a rare situation, but optimal treatment of associated hydrocephalus in these children has remained undetermined. METHODS: Twenty-nine children treated between January 2005 and December 2015 for a metastatic PFT associated with hydrocephalus constituted the study cohort. Patients were divided into three groups: ventriculoperitoneal shunt (VPS), endoscopic third ventriculostomy (ETV), and temporary ventricular drainage before or during tumor resection (PVD). RESULTS: There were 4 VPS, 18 ETV, and 7 PVD. The global incidence of CSF diversion failure was 52%. No case of dysfunction or dissemination of metastatic cells occurred in the VPS group. Recurrence of hydrocephalus occurred in 55% of the ETV group. Presence of multiple macroscopic metastases and CSF metastatic cells after tumor surgery was associated with ETV failure. Fifty-seven percent of the children in the PVD group were reoperated after an average time of 53 days. Specific oncologic treatment was initiated earlier in the VPS group (11 days) compared to ETV (27 days) and PVD (23 days) groups. CONCLUSIONS: ETV should be avoided in cases of multiple macroscopic metastases, and children who underwent ETV must be followed carefully when metastatic cells are present in CSF after tumor surgery. External ventricular drainage before or during surgical removal should not be considered as a final option to treat hydrocephalus. VPS remains a safe alternative in this situation and allows an early specific oncologic treatment.
Authors: Matthew G Stovell; Rasheed Zakaria; Jonathan R Ellenbogen; Mathew J Gallagher; Michael D Jenkinson; Caroline Hayhurst; Conor L Mallucci Journal: J Neurosurg Pediatr Date: 2016-02-12 Impact factor: 2.375
Authors: A Fiorillo; G Maggi; A Martone; R Migliorati; R D'Amore; E Alfieri; N Greco; S Cirillo; I Marano Journal: J Neurooncol Date: 2001-05 Impact factor: 4.130
Authors: Jay Riva-Cambrin; Allan S Detsky; Maria Lamberti-Pasculli; Michael A Sargent; Derek Armstrong; Rahim Moineddin; D Douglas Cochrane; James M Drake Journal: J Neurosurg Pediatr Date: 2009-05 Impact factor: 2.375
Authors: Richard G Grundy; Sophie A Wilne; Claire L Weston; Kath Robinson; Linda S Lashford; James Ironside; Tim Cox; W Kling Chong; Richard H A Campbell; Cliff C Bailey; Rao Gattamaneni; Sue Picton; Nicky Thorpe; Conor Mallucci; Martin W English; Jonathan A G Punt; David A Walker; David W Ellison; David Machin Journal: Lancet Oncol Date: 2007-08 Impact factor: 41.316
Authors: Fabio Frisoli; Michael Kakareka; Kristina A Cole; Angela J Waanders; Phillip B Storm; Shih-Shan Lang Journal: Childs Nerv Syst Date: 2019-03-20 Impact factor: 1.475